AstraZeneca PLC (AZNCF)
OTCMKTS · Delayed Price · Currency is USD
169.85
-2.25 (-1.31%)
Oct 9, 2025, 3:54 PM EDT
AstraZeneca Employees
AstraZeneca had 94,300 employees as of December 31, 2024. The number of employees increased by 4,400 or 4.89% compared to the previous year.
Employees
94,300
Change (1Y)
4,400
Growth (1Y)
4.89%
Revenue / Employee
$599,162
Profits / Employee
$87,964
Market Cap
266.87B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 94,300 | 4,400 | 4.89% |
Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
Dec 31, 2022 | 83,500 | 400 | 0.48% |
Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
Dec 31, 2020 | 76,100 | 5,500 | 7.79% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Elite Pharmaceuticals | 68 |
Glass House Brands | 374 |
Northwest Biotherapeutics | 25 |
CytoDyn | 13 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Jushi Holdings | 1,234 |
Nuo Therapeutics | 9 |
AstraZeneca News
- 16 hours ago - Collaboration Between Turbine and AstraZeneca (AZN) Enhances ADC Discovery - GuruFocus
- 16 hours ago - AstraZeneca (AZN) Unaffected by Potential Tariffs on Generic Drugs - GuruFocus
- 18 hours ago - Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery - PRNewsWire
- 1 day ago - AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study - Nasdaq
- 2 days ago - AstraZeneca (AZN) Reports Success in Phase 3 Hypertension Trial - GuruFocus
- 2 days ago - AZN: Baxdrostat Shows Promising Results in Phase III Trial - GuruFocus
- 2 days ago - AstraZeneca succeeds in late-stage trial for blood pressure therapy - Seeking Alpha
- 2 days ago - Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension - Business Wire